News & Updates

Show Multimedia Only

Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC

05 Nov 2025 by

An updated analysis of MARIPOSA reveals significant reductions in the incidence of MET and EGFR resistance alterations with first-line amivantamab plus lazertinib compared with osimertinib, with no upregulation in other resistance pathways, in patients with nonsmall cell lung cancer (NSCLC).

Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC

05 Nov 2025

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

05 Nov 2025 by

Treatment with tislelizumab results in longer overall survival (OS), prolonged progression-free survival (PFS), higher objective response rates (ORRs), more durable responses, and fewer grade ≥3 treatment-emergent (TEAEs) and treatment-related adverse events (TRAEs) compared with docetaxel, according to the RATIONALE-303 study.

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

05 Nov 2025

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

04 Nov 2025 by

Neoadjuvant treatment with tiragolumab plus atezolizumab, with or without chemotherapy, is feasible in advanced resectable non-small cell lung cancer (NSCLC), having an acceptable safety profile and yielding major pathologic response (MPR) rates comparable to that observed with other perioperative immunotherapy plus chemotherapy regimens, according to the phase II SKYSCRAPER-05 trial.

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

04 Nov 2025

DNMT3A mutations predict PD-(L)1 blockade efficacy in NSCLC

04 Nov 2025

Some patients with nonsmall-cell lung cancer (NSCLC) have somatic DNA methyltransferase 3A (DNMT3A) mutations, which are associated with a reduced DNMT3A expression and a favourable immunophenotype, reveals a study.

DNMT3A mutations predict PD-(L)1 blockade efficacy in NSCLC

04 Nov 2025

Patients with advanced NSCLC get durable benefits with frontline cemiplimab plus chemo

03 Nov 2025 by

In the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), the combination of cemiplimab plus chemotherapy continued to provide superior benefits compared with chemotherapy alone, according to 5-year data from the phase III EMPOWER-Lung part 2 trial.

Patients with advanced NSCLC get durable benefits with frontline cemiplimab plus chemo

03 Nov 2025

Past COVID-19 infection linked to poor sleep

02 Nov 2025

People with a history of COVID-19 appear to have reduced sleep quality, as reported in a study.

Past COVID-19 infection linked to poor sleep

02 Nov 2025

Plant-based foods, probiotic drinks may help fight allergic asthma

02 Nov 2025 by

Certain plant-based foods and probiotic drinks appear to be associated with reduced prevalence of allergic asthma among young Chinese adults in Singapore, according to a study.

Plant-based foods, probiotic drinks may help fight allergic asthma

02 Nov 2025

Original New Drug Application Approvals by US FDA (16-30 September 2025)

31 Oct 2025

New drug applications approved by US FDA as of 16-30 September 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 September 2025)

31 Oct 2025

Colchicine flops for long COVID treatment

29 Oct 2025

Treatment with colchicine does not appear to improve functional capacity, respiratory function, or inflammatory markers in adults with long COVID, as shown in a study.

Colchicine flops for long COVID treatment

29 Oct 2025

Does morphine use help with breathlessness?

24 Oct 2025

Treatment with oral morphine falls short of improving breathlessness due to cardiorespiratory conditions, as shown in a study.

Does morphine use help with breathlessness?

24 Oct 2025

News & Updates

Filter by Specialty:

Specialty:

Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC

Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

DNMT3A mutations predict PD-(L)1 blockade efficacy in NSCLC

DNMT3A mutations predict PD-(L)1 blockade efficacy in NSCLC

Patients with advanced NSCLC get durable benefits with frontline cemiplimab plus chemo

Patients with advanced NSCLC get durable benefits with frontline cemiplimab plus chemo

Past COVID-19 infection linked to poor sleep

Past COVID-19 infection linked to poor sleep

Plant-based foods, probiotic drinks may help fight allergic asthma

Plant-based foods, probiotic drinks may help fight allergic asthma

Original New Drug Application Approvals by US FDA (16-30 September 2025)

Original New Drug Application Approvals by US FDA (16-30 September 2025)

Colchicine flops for long COVID treatment

Colchicine flops for long COVID treatment

Does morphine use help with breathlessness?

Does morphine use help with breathlessness?